Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures post ...

This test is useful for those who have recurrent blackouts, unexplained falls, memory gaps, panic attacks, and do do not ...

Future treatment resistance to focal epilepsy therapy was significantly more likely in individuals who reported suicidal ...

Hasty had a message for what proclaiming Thursday, March 26, 2026 as Epilepsy Awareness Day could change about the city of ...

If you did not know, Purple Day takes place every year on March 26, and it is a global movement to increase awareness and reduce stigma around epilepsy. About 1 in 26 people will develop epilepsy ...

This morning on “The Rhode Show” we welcomed Dr. Preeti Gupta, a board-certified neurologist specializing in epilepsy, and the Founder of the NeuroLogic Center for Seizures + Epilepsy.

Stoke Therapeutics is developing a drug designed to reduce seizures and restore some of their lost developmental function.

Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase 2.

Despite trying antidepressants and CBT, the “panic” episodes only worsened, especially in the three years before the test.

EastEnders viewers were left feeling rather confused after a “silly” blunder hit the BBC soap earlier this week. In an episode that aired on Monday (16 March), it was revealed by newcomer Bea Pollard ...

It was like my body was turning against me, and there wasn’t anything I could do,” Arielle Hoffman told The Post.

Ovid Therapeutics (OVID) shares jumped over 40% premarket as the biopharmaceutical company reported favorable safety and tolerability results for the 7 mg dose of its OV329 epilepsy drug, while ...